| Literature DB >> 21350114 |
Alka M Kanaya1, Nancy Adler, Howard H Moffet, Jennifer Liu, Dean Schillinger, Alyce Adams, Ameena T Ahmed, Andrew J Karter.
Abstract
OBJECTIVE: Ethnic minorities with diabetes typically have lower rates of cardiovascular outcomes and higher rates of end-stage renal disease (ESRD) compared with whites. Diabetes outcomes among Asian and Pacific Islander subgroups have not been disaggregated. RESEARCH DESIGN AND METHODS: We performed a prospective cohort study (1996-2006) of patients enrolled in the Kaiser Permanente Northern California Diabetes Registry. There were 64,211 diabetic patients, including whites (n = 40,286), blacks (n = 8,668), Latinos (n = 7,763), Filipinos (n = 3,572), Chinese (n = 1,823), Japanese (n = 951), Pacific Islanders (n = 593), and South Asians (n = 555), enrolled in the registry. We calculated incidence rates (means ± SD; 7.2 ± 3.3 years follow-up) and created Cox proportional hazards models adjusted for age, educational attainment, English proficiency, neighborhood deprivation, BMI, smoking, alcohol use, exercise, medication adherence, type and duration of diabetes, HbA(1c), hypertension, estimated glomerular filtration rate, albuminuria, and LDL cholesterol. Incidence of myocardial infarction (MI), congestive heart failure, stroke, ESRD, and lower-extremity amputation (LEA) were age and sex adjusted.Entities:
Mesh:
Year: 2011 PMID: 21350114 PMCID: PMC3064053 DOI: 10.2337/dc10-1964
Source DB: PubMed Journal: Diabetes Care ISSN: 0149-5992 Impact factor: 19.112
Baseline characteristics of 64,211 participants with diabetes by race/ethnic group*
| Characteristics | White | African American | Latino | Filipino | Chinese | Japanese | South Asian | Pacific Islander |
|---|---|---|---|---|---|---|---|---|
| 40,286 | 8,668 | 7,763 | 3,572 | 1,823 | 951 | 555 | 593 | |
| Follow-up time (mean ± SD) | 7.0 ± 8.9 | 7.3 ± 3.2 | 7.5 ± 3.2 | 7.5 ± 3.2 | 7.8 ± 3.1 | 8.0 ± 3.3 | 7.4 ± 3.3 | 7.0 ± 3.3 |
| Female sex | 45 | 53 | 49 | 51 | 42 | 52 | 30 | 44 |
| Age (years) (mean ± SD) | 61 ± 13 | 59 ± 12 | 58 ± 12 | 56 ± 11 | 60 ± 12 | 63 ± 11 | 53 ± 11 | 54 ± 10 |
| Education achieved | ||||||||
| <High school | 13 | 17 | 36 | 13 | 19 | 9 | 13 | 26 |
| High school graduate/GED | 30 | 26 | 28 | 15 | 20 | 30 | 14 | 33 |
| Some college | 32 | 38 | 24 | 25 | 24 | 29 | 18 | 27 |
| College graduate or higher | 25 | 18 | 12 | 47 | 37 | 33 | 55 | 14 |
| Neighborhood deprivation index | ||||||||
| Fourth quartile (poorest) | 11.6 | 47.4 | 31.0 | 19.5 | 13.2 | 12.0 | 12.8 | 21.8 |
| Limited English proficiency | ||||||||
| No English spoken | 0.7 | 0.1 | 13.9 | 8.2 | 33.5 | 5.8 | 9.5 | 6.8 |
| BMI (kg/m2) | ||||||||
| Underweight (<19.0) | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 |
| Normal (19.0–24.9) | 21 | 14 | 16 | 21 | 27 | 19 | 28 | 22 |
| Overweight (25.0–29.9) | 36 | 36 | 39 | 23 | 23 | 21 | 21 | 37 |
| Obese (≥30.0) | 43 | 48 | 45 | 55 | 48 | 59 | 50 | 40 |
| Current smoker (%) | 12 | 16 | 11 | 9 | 4 | 9 | 5 | 14 |
| Alcohol (drinks/week) | ||||||||
| Moderate use (7–19) | 7 | 4 | 5 | 2 | 2 | 2 | 7 | 4 |
| Heavy use (≥20) | 2 | 1 | 2 | 0 | 0 | 1 | 1 | 1 |
| Uses exercise as part of treatment | 48 | 50 | 47 | 59 | 47 | 52 | 52 | 57 |
| Diabetes type | ||||||||
| Type 1 | 7 | 4 | 3 | 1 | 2 | 1 | 5 | 3 |
| Type 2, using insulin | 20 | 26 | 20 | 12 | 13 | 17 | 13 | 19 |
| Type 2, oral hypoglycemic | 51 | 54 | 56 | 66 | 47 | 58 | 62 | 60 |
| Type 2, diet controlled | 22 | 16 | 21 | 20 | 27 | 23 | 20 | 18 |
| First-degree family history of diabetes | 51 | 65 | 72 | 59 | 53 | 57 | 69 | 72 |
| Diabetes duration (years) | ||||||||
| 0–9 | 61 | 61 | 62 | 72 | 65 | 62 | 69 | 69 |
| 10–19 | 24 | 25 | 25 | 20 | 22 | 22 | 34 | 21 |
| ≥20 | 16 | 14 | 13 | 8 | 12 | 16 | 8 | 10 |
| HbA1c category (%) | ||||||||
| <7 | 28 | 25 | 23 | 18 | 28 | 25 | 20 | 16 |
| 7–8 | 24 | 20 | 19 | 21 | 23 | 26 | 25 | 17 |
| 8–10 | 30 | 28 | 31 | 33 | 31 | 33 | 34 | 32 |
| ≥10 | 18 | 27 | 27 | 28 | 18 | 16 | 21 | 35 |
| Self-monitored blood glucose per guidelines | 46 | 34 | 38 | 33 | 34 | 42 | 38 | 29 |
| History of hypertension | 68 | 72 | 56 | 61 | 63 | 65 | 47 | 62 |
| HDL <45 mg/dL for women or <35 mg/dL for men | 63 | 43 | 62 | 56 | 50 | 54 | 58 | 62 |
| LDL ≥100 mg/dL | 87 | 89 | 87 | 91 | 86 | 89 | 89 | 91 |
| Triglycerides ≥200 mg/dL | 46 | 20 | 46 | 38 | 38 | 47 | 37 | 43 |
| Taking a cholesterol-lowering medication | 14 | 10 | 10 | 15 | 14 | 21 | 11 | 15 |
| Microalbuminuria | 14 | 15 | 14 | 17 | 15 | 18 | 10 | 17 |
| eGFR (mL/min) | ||||||||
| ≥90 | 16 | 29 | 29 | 26 | 22 | 22 | 27 | 24 |
| 60–89 | 53 | 49 | 50 | 51 | 54 | 55 | 60 | 50 |
| 30–59 | 28 | 17 | 17 | 19 | 20 | 19 | 11 | 19 |
| 15–29 | 2 | 3 | 2 | 2 | 3 | 3 | 1 | 3 |
| <15 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 5 |
*Values represent % unless otherwise stated.
Crude age- and sex-adjusted incidence rates and fully adjusted rate ratios* of each outcome by racial subgroup, DISTANCE study, 1996–2006
| Outcomes | White | African American | Latino | All Asians | Filipino | Chinese | Japanese | South Asian | Pacific Islander |
|---|---|---|---|---|---|---|---|---|---|
| MI: | 4,276/36,185 | 658/8,131 | 559/7,257 | 529/6,550 | 287/3,399 | 124/1,743 | 74/899 | 44/509 | 66/537 |
| Total person-years of follow-up | 249,426 | 58,336 | 53,160 | 49,010 | 24,956 | 13,460 | 7,031 | 3,563 | 3,572 |
| Unadjusted rate (95% CI) | 17.1 (16.6–17.7) | 11.3 (10.4–12.2) | 10.5 (9.7–11.4) | 10.8 (9.9–11.8) | 11.5 (10.2–12.9) | 9.2 (7.7–11.0) | 10.5 (8.3–13.2) | 12.3 (9.0–16.6) | 18.5 (14.3–23.5) |
| Age- and sex-adjusted rate (95% CI) | 5.9 (5.7–6.2) | 4.3 (3.9–4.8) | 4.2 (3.8–4.7) | 4.1 (3.7–4.6) | 4.7 (4.0–5.4) | 3.6 (2.6–4.8) | 3.3 (2.3–4.4) | 5.9 (3.3–9.1) | 10.1 (6.8–14.0) |
| Fully adjusted rate ratio (95% CI) | 1.0 (reference) | 0.66 (0.47–0.91) | 0.63 (0.43–0.91) | 0.58 (0.40–0.85) | 0.40 (0.21–0.77) | 0.41 (0.18–0.93) | 0.67 (0.34–1.31) | 1.99 (0.97–4.09) | 1.05 (0.39–2.84) |
| CHF: | 3,400/36,995 | 794/8,021 | 478/7,420 | 355/6,602 | 193/3,415 | 81/1,744 | 55/908 | 26/535 | 35/547 |
| Total person-years of follow-up | 261,568 | 57,636 | 55,154 | 50,407 | 25,624 | 13,662 | 7,243 | 3,878 | 3,804 |
| Unadjusted rate (95% CI) | 13.0 (12.6–13.4) | 13.8 (12.8–14.8) | 8.7 (7.9–9.5) | 7.0 (6.3–7.8) | 7.5 (6.5–8.7) | 5.9 (4.7–7.4) | 7.6 (5.7–9.9) | 6.7 (4.4–9.8) | 9.2 (6.4–12.8) |
| Age- and sex-adjusted rate (95% CI) | 4.2 (4.1–4.4) | 5.2 (4.7–5.8) | 3.5 (3.1–4.0) | 2.8 (2.4–3.3) | 3.5 (2.9–4.2) | 2.5 (1.0–4.3) | 2.6 (1.7–3.6) | 4.4 (0.9–9.2) | 4.0 (2.4–5.9) |
| Fully adjusted rate ratio (95% CI) | 1.0 (reference) | 1.24 (0.92–1.68) | 0.64 (0.42–0.99) | 0.80 (0.53–1.21) | 0.79 (0.43–1.46) | 0.74 (0.35–1.56) | 0.55 (0.22–1.33) | 2.29 (0.92–5.65) | 0.73 (0.18–2.96) |
| Stroke: | 3,212/38,376 | 713/8,325 | 445/7,531 | 417/6,668 | 194/3,455 | 130/1,757 | 67/913 | 26/543 | 38/579 |
| Total person-years of follow-up | 266,344 | 59,168 | 55,446 | 50,324 | 25,710 | 13,527 | 7,134 | 3,953 | 3,961 |
| Unadjusted rate (95% CI) | 12.1 (11.6–12.5) | 12.1 (11.2–13.0) | 8.0 (7.3–8.8) | 8.3 (7.5–9.1) | 7.5 (6.5–8.7) | 9.6 (8.0–11.4) | 9.4 (7.3–11.9) | 6.6 (4.3–9.6) | 9.6 (6.8–13.2) |
| Age- and sex-adjusted rate (95% CI) | 3.9 (3.6–4.1) | 5.0 (4.2–5.8) | 3.1 (2.8–3.6) | 3.1 (2.7–3.6) | 3.2 (2.6–3.9) | 3.2 (2.5–4.0) | 2.8 (1.7–4.3) | 3.4 (1.5–5.8) | 5.2 (2.8–8.3) |
| Fully adjusted rate ratio (95% CI) | 1.0 (reference) | 0.73 (0.50–1.06) | 0.59 (0.39–0.90) | 0.58 (0.38–0.87) | 0.65 (0.37–1.14) | 0.28 (0.11–0.70) | 0.85 (0.45–1.61) | 0.52 (0.13–2.10) | 0.53 (0.13–2.14) |
| ESRD: | 1,080/39,898 | 528/8,519 | 356/7,648 | 337/6,797 | 188/3,512 | 79/1,801 | 57/937 | 13/547 | 39/576 |
| Total person-years of follow-up | 279,802 | 61,040 | 56,507 | 51,465 | 26,128 | 13,932 | 7,379 | 4,025 | 3,955 |
| Unadjusted rate (95% CI) | 3.9 (3.6–4.1) | 8.7 (7.9–9.4) | 6.3 (5.7–7.0) | 6.5 (5.9–7.3) | 7.2 (6.2–8.3) | 5.7 (4.5–7.1) | 7.7 (5.9–10.0) | 3.2 (1.7–5.5) | 9.9 (7.0–13.5) |
| Age- and sex-adjusted rate (95% CI) | 2.4 (2.1–2.8) | 4.8 (3.5–6.1) | 3.0 (2.4–3.7) | 2.9 (2.0–4.0) | 3.9 (2.3–5.7) | 1.9 (1.4–2.5) | 3.0 (1.6–4.6) | 1.1 (0.5–2.1) | 5.0 (2.7–7.8) |
| Fully adjusted rate ratio (95% CI) | 1.0 (reference) | 3.37 (2.09–5.43) | 1.30 (0.65–2.59) | 1.77 (0.98–3.21) | 2.09 (0.93–4.67) | 1.47 (0.51–4.23) | 2.09 (0.81–5.40) | 0.0 | 0.0 |
| LEA: | 1,477/39,659 | 390/8,503 | 293/7,656 | 107/6,872 | 53/3,561 | 29/1,812 | 21/946 | 4/553 | 24/589 |
| Total person-years of follow-up | 277,454 | 61,304 | 56,698 | 52,526 | 26,793 | 14,105 | 7,547 | 4,081 | 4,058 |
| Unadjusted rate (95% CI) | 5.3 (5.1–5.6) | 6.4 (5.7–7.0) | 5.2 (4.6–5.8) | 2.0 (1.7–2.5) | 2.0 (1.5–2.6) | 2.1 (1.4–3.0) | 2.8 (1.7–4.3) | 1.0 (0.3–2.5) | 5.9 (3.8–8.8) |
| Age- and sex-adjusted rate (95% CI) | 2.4 (2.1–2.6) | 2.6 (2.2–3.1) | 2.1 (1.8–2.5) | 0.9 (0.5–1.2) | 0.7 (0.5–1.0) | 0.7 (0.3–1.1) | 1.3 (0.5–2.4) | 1.0 (−0.1 to 3.5) | 2.6 (1.5–4.0) |
| Fully adjusted rate ratio (95% CI) | 1.0 (reference) | 0.75 (0.40–1.40) | 1.17 (0.65–2.10) | 0.29 (0.12–0.69) | 0.34 (0.10–1.14) | 0.18 (0.02–1.31) | 0.26 (0.04–1.90) | 0.38 (0.05–3.11) | 0.0 |
*Fully adjusted rate ratio comparing the rate in each ethnic group with that of whites using a Poisson regression model.
Figure 1HRs and 95% CIs for each ethnic group (vs. whites [reference group]) for each diabetes complication.